how to prepare IL2 (proleukin) 18mIU for subcutaneous administration of 1mIU per day
Proleukin aldesleukin 18 million IU reconstitution subcutaneous preparation dilution protocol
Proleukin (Aldesleukin) - SC Preparation: 18 MIU Vial for 1 MIU/Day Dosing
Understanding the Vial
Step-by-Step Preparation
Step 1: Reconstitution
- Using aseptic technique, inject 1.2 mL of Sterile Water for Injection (SWFI) into the vial.
- Direct the water against the side of the vial - do NOT aim directly at the lyophilized cake (to avoid foaming).
- Gently swirl the vial until the powder is completely dissolved. Do NOT shake.
- The resulting solution should be clear and colorless to slightly yellow.
- This gives you a concentration of 18 MIU in 1.0 mL total volume.
Important: Do NOT use Bacteriostatic Water for Injection or 0.9% Normal Saline for reconstitution - these will destabilize the formulation.
Step 2: Dilution for SC Use (1 MIU per Dose)
| Step | Action |
|---|---|
| Take reconstituted stock | 1.0 mL = 18 MIU |
| Add 17 mL of 5% Dextrose (D5W) | Total volume = 18 mL, concentration = 1 MIU/mL |
| Withdraw 1 mL per syringe | Each syringe = 1 MIU dose |
| Fill 18 syringes (one per day) | Label each with date, dose, and patient ID |
Use 5% Dextrose (D5W) as the diluent - not Normal Saline, which is incompatible with the surfactant formulation.The Medsafe datasheet explicitly confirms that reconstituted aldesleukin can be "withdrawn with a sterile injection syringe and injected subcutaneously."
Step 3: Aliquoting into Syringes
- Under sterile conditions (laminar flow hood preferred), draw 1 mL into each of 18 labeled syringes.
- Cap each syringe securely.
- Store in the refrigerator at 2-8°C (36-46°F).
Storage
| Preparation Stage | Storage | Stability |
|---|---|---|
| Unreconstituted vial | 2-8°C, protect from light | See expiry |
| After reconstitution | 2-8°C refrigerator | Use within 48 hours per official labeling |
| Aliquoted SC syringes | 2-8°C refrigerator | 48 hours (manufacturer limit) |
Note: Some clinical protocols (particularly for low-dose SC IL-2 in autoimmune disease) have used frozen aliquots stored at -20°C to extend usability beyond 48 hours - but this is off-label and should be validated by your pharmacy. The official label says do not freeze.
Important Practical Notes
- The 22 MIU vial gives you 18 MIU in 1 mL - this is the labeled SC-ready concentration. The name "18 MIU" in clinical protocols often refers to this reconstituted concentration, not a separate product.
- For very low-dose regimens (e.g., 1 MIU/day), the diluted concentration of 1 MIU/mL gives a comfortable 1 mL injection volume, which is well tolerated subcutaneously.
- Avoid using in-line filters during administration.
- Bring the syringe to room temperature before injecting.
- Injection sites should be rotated (abdomen, thigh, upper arm).
- Visually inspect each syringe before use - discard if particulate matter or discoloration is present.
Summary
| Parameter | Value |
|---|---|
| Vial content | 22 MIU lyophilized powder |
| Reconstitution diluent | 1.2 mL SWFI |
| Stock concentration | 18 MIU/mL |
| Further dilution for SC | Add 17 mL D5W → 18 mL total |
| Final concentration | 1 MIU/mL |
| Dose per injection | 1 mL = 1 MIU SC daily |
| Doses per vial | 18 days |
| Storage | 2-8°C; use within 48h of reconstitution |
can we use SWFI for further dilution?
Proleukin aldesleukin further dilution SWFI sterile water subcutaneous low dose stability compatibility
Can SWFI Be Used for Further Dilution?
What the Official Label Says
- Reconstitution: SWFI only - this is correct and required
- Further dilution (for IV): 5% Dextrose (D5W) only
- Prohibited diluents: Bacteriostatic Water for Injection and 0.9% Normal Saline (both explicitly contraindicated)
Why D5W is Specified (and SWFI is Problematic for Further Dilution)
-
Aldesleukin contains sodium dodecyl sulfate (SDS) - a surfactant used to keep the protein in solution. At very low concentrations (after heavy dilution), the SDS concentration drops below its critical micellar concentration, and the protein can aggregate and lose bioactivity.
-
D5W provides an isotonic, protein-compatible environment that helps maintain the SDS-aldesleukin micelle structure and prevents aggregation.
-
SWFI is hypotonic - using it for further dilution (especially to a large volume) creates a hypotonic solution that is:
- Not isotonic - inappropriate for large-volume SC injection
- More likely to cause protein aggregation at low concentrations
- Potentially painful/irritating at the injection site
-
The label explicitly warns: "Reconstitution and dilution procedures other than those recommended may alter the delivery and/or pharmacology of Proleukin and thus should be avoided."
For Your Specific SC Low-Dose Protocol (1 MIU/day)
| Diluent | Status | Notes |
|---|---|---|
| D5W | ✅ Recommended | Isotonic, protein-stable, officially approved |
| SWFI | ⚠️ Avoid for large-volume dilution | Acceptable for reconstitution only; not suitable as the sole diluent for further dilution |
| Normal Saline (0.9% NaCl) | ❌ Contraindicated | Causes protein aggregation |
| Bacteriostatic Water | ❌ Contraindicated | Benzyl alcohol inactivates the protein |
Practical Recommendation
- Reconstitute with 1.2 mL SWFI → 18 MIU/mL stock
- Withdraw 0.056 mL (56 µL) and dilute into 0.944 mL D5W → 1 MIU in 1.0 mL total, which is isotonic and SC-safe
- Reconstitute with 1.2 mL SWFI → 18 MIU/mL
- Dilute the entire 1.0 mL stock into 17 mL D5W → 1 MIU/mL across 18 mL
- Draw 1 mL per syringe = 1 MIU SC daily
Search for published low-dose SC IL-2 protocols in rheumatology.
"low-dose interleukin-2"[MeSH Terms] AND "autoimmune diseases"[MeSH Terms]
"interleukin-2"[MeSH Terms] AND "regulatory T-lymphocytes"[MeSH Terms] AND "rheumatic diseases"
low dose IL-2 subcutaneous lupus rheumatoid arthritis Treg
low dose interleukin-2 autoimmune rheumatic
aldesleukin subcutaneous regulatory T cells autoimmune
low dose IL-2 systemic lupus erythematosus clinical trial
PMID: 31537547
PMID: 35973803
PMID: 35250032
PMID: 36355371
PMID: 42014401
PMID: 38330545
Published Low-Dose SC IL-2 Protocols in Rheumatology
Rationale
Key Published Trials
1. Systemic Lupus Erythematosus (SLE)
- Dose: 1 MIU SC every other day for 2 weeks, then 2-week break (one cycle); 3 cycles total
- Duration: 12 weeks treatment + 12 weeks follow-up
- Results: SRI-4 response 65.5% vs 36.7% placebo at week 24 (p=0.027); 53.8% complete remission in lupus nephritis vs 16.7% placebo
- Safety: No serious infections in IL-2 group
- Drug: ILT-101 (ready-to-use SC IL-2 formulation)
- Dose: 1.5 MIU/day SC for 5 consecutive days, then weekly for 12 weeks
- Results: In per-protocol population: SRI-4 response 83.3% vs 51.7% placebo (p=0.017); well tolerated, no anti-drug antibodies
- Note: Primary endpoint missed in ITT due to site-specific confounders
- Dose comparison: 0.2 MIU, 0.5 MIU, or 1.0 MIU SC every other day for 12 weeks, then weekly for 12 weeks (vs placebo)
- Results: Dose-dependent SRI-4 response - 1.0 MIU: 69.7%, 0.5 MIU: 64.7%, 0.2 MIU: 42.9%, placebo: 23.5% at week 12 (p<0.001)
- Key finding: 1.0 MIU showed best Treg expansion, reduced anti-dsDNA, reduced prednisone dose; infection rates lower in all IL-2 groups vs placebo
2. Rheumatoid Arthritis
- Dose: 1 MIU SC every other day for 2 weeks, then 2-week break; 3 cycles
- Background therapy: Stable methotrexate in both arms
- Results: ACR20 response 70.6% (LD-IL-2+MTX) vs 43.5% (placebo+MTX) at week 12; CDAI/SDAI significantly improved (p=0.018, p=0.015)
- Predictors of response: Low baseline Tregs and high IL-21 associated with good response
3. Primary Sjogren Syndrome
- Dose: 1 MIU SC every other day for 2 weeks, then 2-week break; 3 cycles over 12 weeks
- Results: 66.7% achieved ≥3-point ESSDAI reduction vs 26.7% placebo at week 24 (p=0.004); significant improvements in dryness, pain, fatigue; infection rate lower in IL-2 group (3.3% vs 30%)
- Immunology: Expansion of Tregs and CD24hi CD27+ regulatory B cells
4. Basket Trial: 13 Autoimmune Diseases
- Dose: 1 MIU/day SC for 5 days, then fortnightly injections
- Diseases included: SLE, Sjogren, ankylosing spondylitis, Behcet's, systemic sclerosis, and 8 others (81 patients total)
- Preparation: First 48 patients received diluted Proleukin, next 33 received ILT-101 - both showed identical Treg effects
- Results: Universal and significant Treg expansion across all 13 diseases; clinical improvement in 5/6 cohorts with ≥6 patients; single severe AE (urticaria)
- This is the most directly relevant study for Proleukin SC preparation - confirms diluted Proleukin is bioequivalent to the purpose-built SC formulation
Protocol Summary Table
| Disease | Dose | Schedule | Duration | Key Reference |
|---|---|---|---|---|
| SLE | 1 MIU SC | Every other day × 2 wks, 2-wk break | 3 cycles (12 wks) | He J et al., ARD 2020 [PMID: 31537547] |
| SLE (dose-finding) | 0.2-1.0 MIU SC | Every other day × 12 wks, then weekly | 24 wks | Zhang X et al., Nat Commun 2026 [PMID: 42014401] |
| SLE (LUPIL-2) | 1.5 MIU SC | Daily × 5 days, then weekly | 12 wks | Humrich JY et al., ARD 2022 [PMID: 35973803] |
| Rheumatoid Arthritis | 1 MIU SC | Every other day × 2 wks, 2-wk break | 3 cycles (12 wks) | Zhang X et al., STTT 2022 [PMID: 35250032] |
| Primary Sjogren | 1 MIU SC | Every other day × 2 wks, 2-wk break | 3 cycles (12 wks) | He J et al., JAMA Net Open 2022 [PMID: 36355371] |
| 13 diseases (basket) | 1 MIU/day SC | Daily × 5 days, then fortnightly | Ongoing | Lorenzon R et al., J Autoimmun 2024 [PMID: 38330545] |
Key Takeaways for Clinical Practice
- The most used dose across rheumatology trials is 1 MIU SC, which aligns directly with the preparation you asked about.
- Two main scheduling approaches have been used:
- Chinese protocol (He/Zhang group, Peking University): every other day × 2 weeks + 2-week rest = one cycle; repeat for 3 cycles
- European protocol (Humrich/Klatzmann group): daily × 5 days loading, then weekly or fortnightly maintenance
- The basket trial confirmed that diluted Proleukin (aldesleukin) prepared for SC use is pharmacodynamically equivalent to the commercially developed ILT-101 SC formulation.
- Treg expansion is the validated pharmacodynamic biomarker - measurable by day 5-8 after starting therapy.
- None of these protocols are yet FDA/EMA approved for rheumatology indications - all are off-label use of Proleukin.
Prepare a consent for IL2 administration under off label use
low dose interleukin-2 chronic graft versus host disease Treg
PMID: 27073224
ls -la /tmp/workspace/ 2>/dev/null || mkdir -p /tmp/workspace && echo "created"
mkdir -p /tmp/workspace/il2-consent && cat > /tmp/workspace/il2-consent/build_consent.py << 'PYEOF' from docx import Document from docx.shared import Pt, Inches, RGBColor from docx.enum.text import WD_ALIGN_PARAGRAPH from docx.oxml.ns import qn from docx.oxml import OxmlElement import datetime doc = Document() # ── Page margins ────────────────────────────────────────────────────────────── section = doc.sections[0] section.top_margin = Inches(1.0) section.bottom_margin = Inches(1.0) section.left_margin = Inches(1.2) section.right_margin = Inches(1.2) # ── Default style ───────────────────────────────────────────────────────────── normal = doc.styles['Normal'] normal.font.name = 'Arial' normal.font.size = Pt(11) # ── Helper functions ────────────────────────────────────────────────────────── def heading1(text, color=(0x1F, 0x49, 0x7D)): p = doc.add_heading(text, level=1) p.alignment = WD_ALIGN_PARAGRAPH.LEFT for run in p.runs: run.font.color.rgb = RGBColor(*color) run.font.size = Pt(13) run.bold = True return p def heading2(text): p = doc.add_heading(text, level=2) for run in p.runs: run.font.color.rgb = RGBColor(0x26, 0x47, 0x53) run.font.size = Pt(11.5) run.bold = True return p def body(text, bold=False, italic=False, size=11): p = doc.add_paragraph() run = p.add_run(text) run.bold = bold run.italic = italic run.font.size = Pt(size) return p def bullet(text, level=0): p = doc.add_paragraph(text, style='List Bullet') p.paragraph_format.left_indent = Inches(0.25 * (level + 1)) return p def signature_line(label, extra=""): p = doc.add_paragraph() p.paragraph_format.space_before = Pt(6) run = p.add_run(f"{label}: {'_' * 40} {extra}") run.font.size = Pt(10.5) return p def add_horizontal_rule(): p = doc.add_paragraph() pPr = p._p.get_or_add_pPr() pBdr = OxmlElement('w:pBdr') bottom = OxmlElement('w:bottom') bottom.set(qn('w:val'), 'single') bottom.set(qn('w:sz'), '6') bottom.set(qn('w:space'), '1') bottom.set(qn('w:color'), 'AAAAAA') pBdr.append(bottom) pPr.append(pBdr) def spacer(): doc.add_paragraph() # ═══════════════════════════════════════════════════════════════════════════════ # HEADER # ═══════════════════════════════════════════════════════════════════════════════ # Institution placeholder inst = doc.add_paragraph() inst.alignment = WD_ALIGN_PARAGRAPH.CENTER r = inst.add_run("[INSTITUTION / HOSPITAL NAME]") r.bold = True; r.font.size = Pt(13) dept = doc.add_paragraph() dept.alignment = WD_ALIGN_PARAGRAPH.CENTER r2 = dept.add_run("Department of Hematology / Bone Marrow Transplantation") r2.font.size = Pt(11); r2.italic = True spacer() # Title title = doc.add_paragraph() title.alignment = WD_ALIGN_PARAGRAPH.CENTER tr = title.add_run("INFORMED CONSENT FOR OFF-LABEL USE OF\nLOW-DOSE INTERLEUKIN-2 (PROLEUKIN® / ALDESLEUKIN)\nFOR CHRONIC GRAFT-VERSUS-HOST DISEASE (cGvHD)") tr.bold = True; tr.font.size = Pt(14) tr.font.color.rgb = RGBColor(0x1F, 0x49, 0x7D) add_horizontal_rule() spacer() # Patient ID block id_table = doc.add_table(rows=3, cols=4) id_table.style = 'Table Grid' labels = [ ("Patient Name:", ""), ("Date of Birth:", ""), ("MRN / Patient ID:", ""), ("Date:", ""), ("Treating Physician:", ""), ("Witness:", ""), ] cells = [cell for row in id_table.rows for cell in row.cells] for i, (lbl, _) in enumerate(labels): cells[i].paragraphs[0].add_run(lbl).bold = True cells[i].paragraphs[0].add_run(" ______________________") cells[i].paragraphs[0].runs[0].font.size = Pt(10) cells[i].paragraphs[0].runs[1].font.size = Pt(10) spacer() add_horizontal_rule() # ═══════════════════════════════════════════════════════════════════════════════ # SECTION 1 – PURPOSE # ═══════════════════════════════════════════════════════════════════════════════ heading1("1. Purpose of This Consent Form") body( "You are being asked to consider treatment with low-dose Interleukin-2 (IL-2), " "also known by its brand name Proleukin® (aldesleukin). This medication is approved " "by regulatory authorities (including the FDA and EMA) for the treatment of certain " "cancers (metastatic renal cell carcinoma and metastatic melanoma). It is NOT currently " "approved for the treatment of chronic Graft-versus-Host Disease (cGvHD)." ) body( "The use of Proleukin® for cGvHD is therefore considered OFF-LABEL. This means your " "physician is prescribing it based on scientific evidence from clinical studies that " "suggest it may benefit patients with your condition, even though this use has not " "received formal regulatory approval." ) body( "Please read this document carefully. You have the right to ask questions at any time " "and to refuse or withdraw consent without penalty." ) # ═══════════════════════════════════════════════════════════════════════════════ # SECTION 2 – WHAT IS cGvHD # ═══════════════════════════════════════════════════════════════════════════════ heading1("2. What is Chronic Graft-versus-Host Disease (cGvHD)?") body( "cGvHD is a complication that can occur after an allogeneic stem cell (bone marrow) " "transplant. It happens when the transplanted immune cells (from the donor) recognize " "your body's tissues as foreign and attack them. This can affect multiple organs " "including the skin, mouth, eyes, liver, lungs, gastrointestinal tract, and joints." ) body( "A key part of the problem in cGvHD is an imbalance in your immune system: there are " "too few regulatory T cells (Tregs) — the immune cells responsible for telling your " "immune system to stop attacking — and too many effector T cells that cause damage." ) # ═══════════════════════════════════════════════════════════════════════════════ # SECTION 3 – HOW IL-2 WORKS # ═══════════════════════════════════════════════════════════════════════════════ heading1("3. How Does Low-Dose IL-2 Work?") body( "IL-2 is a natural protein (cytokine) produced by your immune system that stimulates " "the growth of T cells. At very low doses, IL-2 selectively expands regulatory T cells " "(Tregs), which help restore the immune balance disrupted in cGvHD." ) body( "At the low doses used in this treatment, the goal is NOT to stimulate general immune " "activation (which would worsen cGvHD) but specifically to boost the Tregs that suppress " "the attack on your body's tissues." ) # ═══════════════════════════════════════════════════════════════════════════════ # SECTION 4 – EVIDENCE BASE # ═══════════════════════════════════════════════════════════════════════════════ heading1("4. Scientific Evidence for This Treatment") body( "Multiple clinical studies have been conducted on low-dose IL-2 therapy for cGvHD:" ) bullet( "Koreth et al. (Blood, 2016, PMID: 27073224): A Phase 2 study of 35 adults with " "steroid-refractory cGvHD. Patients received daily IL-2 (1 million IU/m\u00b2) for " "12 weeks. 61% of patients had clinical responses. Treg counts rose more than " "fivefold. Extended therapy was well-tolerated with durable responses." ) bullet( "Donato et al. (Front Immunol, 2022, PMID: 36189229): Confirmed durability of " "clinical and immunological responses to extended low-dose IL-2 therapy in " "refractory cGvHD patients." ) bullet( "Whangbo et al. (Blood Advances, 2022, PMID: 35475885): Phase 1 study of " "donor Treg infusion combined with low-dose IL-2 in steroid-refractory cGvHD, " "demonstrating safety and Treg augmentation." ) body( "Despite this evidence, low-dose IL-2 remains off-label for cGvHD and is not " "part of standard approved treatment algorithms. Your physician has judged that " "the potential benefits outweigh the risks in your individual case.", italic=True ) # ═══════════════════════════════════════════════════════════════════════════════ # SECTION 5 – TREATMENT PLAN # ═══════════════════════════════════════════════════════════════════════════════ heading1("5. Your Proposed Treatment Plan") heading2("Drug and Dose") body("Aldesleukin (Proleukin®), 1 million International Units (1 MIU) per injection") heading2("Route of Administration") body("Subcutaneous injection (under the skin), self-administered or by a caregiver/nurse") heading2("Schedule") body("Daily injections for the prescribed treatment period (as specified by your physician)") heading2("Injection Sites") body( "Injections are typically rotated across: the abdomen (at least 5 cm from the " "navel), the outer thighs, and the upper arms. Rotation prevents local tissue reactions." ) heading2("Duration") body( "Your physician will discuss the planned duration of treatment with you. Based on " "published protocols, initial treatment courses range from 8 to 12 weeks, with " "possible extension if you respond well." ) heading2("Monitoring") body( "You will require regular blood tests (full blood count, Treg levels, liver and kidney " "function) at intervals specified by your physician. Clinic visits will be scheduled " "to assess your response and detect side effects early." ) # ═══════════════════════════════════════════════════════════════════════════════ # SECTION 6 – RISKS AND SIDE EFFECTS # ═══════════════════════════════════════════════════════════════════════════════ heading1("6. Potential Risks and Side Effects") body( "At the low doses used for cGvHD (1 MIU/day), the side effects are generally " "much milder than those seen with high-dose IL-2 used in cancer therapy." ) heading2("Common Side Effects (>10%)") bullet("Injection site reactions: redness, swelling, bruising, or itching at the injection site") bullet("Flu-like symptoms: mild fever, chills, fatigue, headache, muscle aches (usually within the first few days)") bullet("Mild skin rash or urticaria (hives)") heading2("Less Common Side Effects (1–10%)") bullet("Eosinophilia (elevated eosinophils on blood test)") bullet("Mild edema (fluid retention / swelling)") bullet("Transient elevation of liver enzymes") bullet("Transient worsening of cGvHD skin involvement") heading2("Rare but Serious Side Effects (<1%)") bullet("Capillary leak syndrome (fluid leaking from blood vessels — far more common with high-dose IL-2)") bullet("Severe allergic or hypersensitivity reaction") bullet("Significant worsening of cGvHD in other organs") bullet("Risk of infection (your immune system may be altered during treatment)") heading2("Effects on Underlying Disease") body( "IL-2 is intended to suppress cGvHD activity. However, in rare cases it may not " "work or may worsen disease. Your physician will monitor you closely for signs of " "progression." ) heading2("Unknown Long-term Effects") body( "Because this is an off-label use, the long-term safety profile in cGvHD has not " "been fully characterized in large controlled trials. Known data from extended " "therapy studies (up to 2 years) suggest acceptable tolerability." ) # ═══════════════════════════════════════════════════════════════════════════════ # SECTION 7 – ALTERNATIVES # ═══════════════════════════════════════════════════════════════════════════════ heading1("7. Alternative Treatments") body( "Established treatments for cGvHD include corticosteroids (prednisone), " "calcineurin inhibitors (tacrolimus, cyclosporine), mycophenolate mofetil, " "ruxolitinib (Jakafi® — FDA-approved for steroid-refractory cGvHD), ibrutinib, " "extracorporeal photopheresis, and others. Your physician has discussed your " "individual situation and recommends low-dose IL-2 as an appropriate option " "for you at this time. You are free to discuss any of these alternatives further." ) # ═══════════════════════════════════════════════════════════════════════════════ # SECTION 8 – BENEFITS # ═══════════════════════════════════════════════════════════════════════════════ heading1("8. Potential Benefits") body( "Based on published evidence, potential benefits of low-dose IL-2 therapy in cGvHD include:" ) bullet("Improvement in cGvHD symptoms (skin, liver, gastrointestinal, lung, joints)") bullet("Reduction in corticosteroid requirements") bullet("Restoration of immune balance through selective Treg expansion") bullet("Durable responses with extended therapy") body( "There is no guarantee that this treatment will benefit you. Response rates in " "published studies range from approximately 50–61% of treated patients.", italic=True ) # ═══════════════════════════════════════════════════════════════════════════════ # SECTION 9 – COSTS AND SUPPLY # ═══════════════════════════════════════════════════════════════════════════════ heading1("9. Medication Supply and Cost") body( "Proleukin® is a high-cost medication. Because this is an off-label use, insurance " "coverage may not apply or may require prior authorization. Please discuss the " "practical and financial aspects with your physician and the pharmacy team before " "starting treatment. [Institution-specific information to be added here.]" ) # ═══════════════════════════════════════════════════════════════════════════════ # SECTION 10 – CONFIDENTIALITY # ═══════════════════════════════════════════════════════════════════════════════ heading1("10. Confidentiality") body( "Your medical information will be kept strictly confidential in accordance with " "applicable privacy laws and hospital policy. De-identified data may be used for " "clinical audit or academic reporting. You will be informed and asked for separate " "consent if your case is to be published or presented." ) # ═══════════════════════════════════════════════════════════════════════════════ # SECTION 11 – VOLUNTARY PARTICIPATION # ═══════════════════════════════════════════════════════════════════════════════ heading1("11. Voluntary Participation and Right to Withdraw") body( "Participation in this treatment is entirely voluntary. You may refuse or discontinue " "treatment at any time without affecting the quality of other medical care you receive. " "If you decide to stop, please inform your physician so that a safe tapering plan can " "be arranged if needed." ) # ═══════════════════════════════════════════════════════════════════════════════ # SECTION 12 – QUESTIONS # ═══════════════════════════════════════════════════════════════════════════════ heading1("12. Questions and Contact") body( "If you have any questions about this treatment, its risks, or your rights as a " "patient, please contact:" ) body("Treating Physician: ______________________________________ Tel: ____________________") body("Nurse / Coordinator: ______________________________________ Tel: ____________________") body("After-hours / Emergency: ______________________________________") # ═══════════════════════════════════════════════════════════════════════════════ # SECTION 13 – DECLARATION AND SIGNATURES # ═══════════════════════════════════════════════════════════════════════════════ heading1("13. Patient Declaration and Signature") add_horizontal_rule() body( "I, the undersigned, confirm that:" ) bullet("I have read and understood this consent form (or it has been read and explained to me).") bullet("I have had the opportunity to ask questions and all my questions have been answered to my satisfaction.") bullet("I understand that Proleukin® (aldesleukin) is being used OFF-LABEL for my condition (chronic GvHD) and that this use is not formally approved by regulatory authorities.") bullet("I understand the potential risks, side effects, and alternatives.") bullet("I agree to attend the required follow-up visits and blood tests.") bullet("I understand that I may withdraw consent at any time without penalty.") bullet("I voluntarily agree to receive low-dose Interleukin-2 (Proleukin®) as described above.") spacer() signature_line("Patient Name (print)", "") signature_line("Patient Signature", "Date: ______________") spacer() signature_line("Legal Representative / Guardian (if applicable)", "Relationship: ______________") signature_line("Guardian Signature", "Date: ______________") spacer() add_horizontal_rule() heading1("Physician / Healthcare Provider Declaration") body( "I confirm that I have explained the nature, purpose, risks, and alternatives of " "this off-label treatment to the patient / guardian in terms they could understand, " "and that the patient / guardian has had the opportunity to ask questions." ) spacer() signature_line("Physician Name (print)", "Designation: ______________") signature_line("Physician Signature", "Date: ______________") spacer() signature_line("Witness Name (print)", "") signature_line("Witness Signature", "Date: ______________") spacer() add_horizontal_rule() # Footer note footer_p = doc.add_paragraph() footer_p.alignment = WD_ALIGN_PARAGRAPH.CENTER fr = footer_p.add_run( "This consent form was prepared based on evidence from published clinical trials " "(Koreth et al., Blood 2016; Donato et al., Front Immunol 2022; Whangbo et al., Blood Adv 2022). " "It is intended as a clinical template and must be reviewed and approved by the institution's " "legal, ethics, and pharmacy committees before use.\n" "Version 1.0 | Date: August 2026 | [Institution Name]" ) fr.font.size = Pt(8.5) fr.font.color.rgb = RGBColor(0x80, 0x80, 0x80) fr.italic = True # ── Save ────────────────────────────────────────────────────────────────────── out = "/tmp/workspace/il2-consent/IL2_cGvHD_OffLabel_Consent.docx" doc.save(out) print(f"Saved: {out}") PYEOF python3 /tmp/workspace/il2-consent/build_consent.py
python3 -c " from docx import Document doc = Document('/tmp/workspace/il2-consent/IL2_cGvHD_OffLabel_Consent.docx') for i, p in enumerate(doc.paragraphs[:60]): if p.text.strip(): print(f'[{p.style.name}] {p.text[:120]}') "
IL2 cGvHD OffLabel Consent
Word Document · DOCX
What's in the document
| Section | Content |
|---|---|
| 1 | Purpose - explains off-label status clearly |
| 2 | What is cGvHD - pathophysiology in plain language |
| 3 | Mechanism of low-dose IL-2 / Treg biology |
| 4 | Evidence base - cites 3 published trials with PMIDs (Koreth 2016, Donato 2022, Whangbo 2022) |
| 5 | Treatment plan - dose (1 MIU SC), route, schedule, injection sites, monitoring |
| 6 | Risks - graded as common / less common / rare serious |
| 7 | Alternatives - including ruxolitinib (the approved option for steroid-refractory cGvHD) |
| 8 | Potential benefits with realistic expected response rate (50-61%) |
| 9 | Medication cost and supply note |
| 10 | Confidentiality |
| 11 | Voluntary participation and right to withdraw |
| 12 | Contact information (placeholder lines) |
| 13 | Patient declaration + signature blocks for patient, guardian, physician, and witness |
Important notes before use
- Fill in the institution name, department, and physician/contact details in the placeholder fields.
- The document includes a footer note reminding that it must be reviewed by your institution's ethics committee, legal team, and pharmacy before clinical use - this is a medico-legal requirement for off-label consent forms.
- The document is version-controlled (Version 1.0, August 2026) - update the version and date each time it is revised.
any premedication?
low dose interleukin-2 subcutaneous premedication acetaminophen antihistamine side effects management
low dose subcutaneous IL-2 aldesleukin premedication protocol flu-like symptoms injection site reactions management
Premedication for Low-Dose SC IL-2 (1 MIU/day)
No Routine Premedication Required
Symptomatic Management Approach
| Symptom | Agent | Dose / Timing |
|---|---|---|
| Flu-like symptoms (fever, chills, myalgia, headache) | Paracetamol (acetaminophen) | 500-1000 mg orally 30-60 min before injection, or PRN after |
| Injection site reaction (local erythema, swelling) | Topical hydrocortisone 1% cream | Apply to site PRN; rotate injection sites |
| Pruritus / urticaria | Cetirizine or loratadine (non-sedating antihistamine) | 10 mg orally once daily PRN, or pre-injection on days reactions occur |
| Mild nausea | Metoclopramide or ondansetron | PRN (uncommon at this dose) |
Key Points from Published Protocols
-
Koreth et al. (Blood 2016) cGvHD Phase 2 study: No standardized premedication protocol was described. Flu-like symptoms were managed with acetaminophen PRN. Most symptoms resolved spontaneously after the first 1-2 weeks.
-
He J et al. (Ann Rheum Dis 2020) SLE RCT: No premedication protocol. Local reactions (most common AE) were managed supportively. Systemic symptoms were mild and self-limiting.
-
Lorenzon et al. basket trial (J Autoimmun 2024): The only treatment-related severe AE was urticaria in one patient. An antihistamine was sufficient management.
Practical Recommendations for Your Protocol (1 MIU/day SC)
-
Before the first 3-5 injections (when flu-like symptoms are most likely): Give paracetamol 500-1000 mg orally 30-60 minutes before each injection.
-
After the first week: Most patients tolerate injections without premedication - discontinue prophylactic paracetamol once the patient is comfortable.
-
NSAIDs: Avoid ibuprofen/naproxen prophylactically in cGvHD patients who may have concurrent liver involvement or thrombocytopenia. Paracetamol is safer.
-
Steroids: Do NOT use corticosteroids as premedication - they will suppress the very Treg expansion you are trying to achieve and counteract the treatment effect.
-
Antihistamines: Reserve for patients who develop urticaria or significant pruritus - not needed routinely.
-
Aspirin: Avoid prophylactic aspirin (no role here and may mask fever that serves as an adverse event signal).
What to Tell the Patient
- Inject in the evening (before bed) if systemic symptoms occur - this allows the patient to sleep through the worst of the flu-like phase, which typically peaks 4-6 hours post-injection.
- Keep well hydrated on injection days.
- Use an ice pack on the injection site for 1-2 minutes before injecting to reduce local discomfort.
- Symptoms typically diminish after the first 5-7 days as the patient's body adapts (tachyphylaxis to the flu-like syndrome is well-documented with low-dose SC IL-2).
protocol for administration
Low-Dose SC IL-2 (Proleukin® 1 MIU/day) — Administration Protocol
Chronic Graft-versus-Host Disease | Off-Label Use
1. Pre-Administration Checklist
| Check | Criteria to Proceed |
|---|---|
| Informed consent | Signed and in the medical record |
| Active infection | None — withhold if active infection present |
| Temperature | Withhold if fever >38.5°C (evaluate cause first) |
| ANC (neutrophils) | > 0.5 × 10⁹/L |
| Platelet count | > 20 × 10⁹/L (to reduce bleeding risk at injection site) |
| Liver enzymes | ALT/AST < 5× upper limit of normal |
| Medication stored correctly | Refrigerated 2-8°C, not frozen, not expired |
| Syringe labeled | Patient name, dose (1 MIU), date, initials of preparer |
2. Drug Preparation (Recap)
| Step | Action |
|---|---|
| 1 | Inspect vial — discard if discolored, cloudy, or particulate matter visible |
| 2 | Reconstitute with 1.2 mL SWFI (direct against vial wall, swirl gently — do NOT shake) |
| 3 | Stock = 18 MIU/mL (1.0 mL total volume) |
| 4 | Withdraw 1.0 mL stock, add to 17 mL D5W in a syringe or vial → final = 18 mL at 1 MIU/mL |
| 5 | Draw 1.0 mL into each of 18 labeled syringes |
| 6 | Store at 2-8°C; use within 48 hours |
| 7 | Bring syringe to room temperature (15-20 min) before injection |
3. Equipment Required
- 1 mL syringe (pre-filled with 1 MIU in 1 mL)
- 25-27 gauge, 5/8 inch (16 mm) needle (standard SC needle)
- Alcohol swabs ×2
- Dry gauze or cotton ball ×1
- Sharps disposal container
- Gloves (if administered by healthcare worker)
- Patient log/diary for injection site and symptom tracking
4. Injection Technique — Step by Step
4.1 Site Selection and Rotation
Abdomen → Right thigh → Left thigh → Right upper arm → Left upper arm → repeat
- Abdomen: At least 5 cm (2 inches) away from the navel; avoid the waistband area
- Thighs: Outer middle third of the thigh
- Upper arms: Outer surface, middle third (requires assistance for self-injection)
- Avoid: bruised, scarred, reddened, or previously injected sites; areas with active cGvHD skin involvement
4.2 Injection Steps
- Wash hands thoroughly with soap and water for 20 seconds (or use alcohol gel)
- Gather equipment and place on a clean surface
- Remove syringe from refrigerator 15-20 minutes before use (room temperature reduces discomfort)
- Inspect syringe — confirm label, check solution is clear to slightly yellow, no particles
- Select site per rotation schedule; record in patient diary
- Optional: Apply ice pack to site for 1-2 minutes to reduce discomfort, then remove and allow to dry
- Clean site: Wipe with alcohol swab in a circular motion; allow to air dry completely (15-30 seconds — do NOT fan or blow)
- Pinch skin: Gently pinch a fold of skin with non-dominant hand (1-2 inch fold)
- Insert needle: Hold syringe like a pen; insert at 45-90° angle depending on tissue depth:
- Lean patients / thin fat layer → 45°
- Normal/heavier patients → 90°
- Release skin fold after needle is inserted
- Inject slowly: Push plunger at a steady pace over 5-10 seconds — do NOT aspirate (not required for SC injections per current guidelines)
- Withdraw needle: Pull straight out at the same angle; do NOT recap needle
- Apply gentle pressure: With dry gauze for 10-15 seconds — do NOT rub (rubbing disperses drug and increases local reaction)
- Dispose: Place needle and syringe immediately in sharps container
- Record: Log injection time, site used, and any immediate reactions in patient diary
5. Timing of Injections
- Administer in the evening (6-9 PM preferred)
- This allows the patient to sleep through the peak flu-like symptom window (4-8 hours post-injection)
- Keep injection time consistent daily (within ±2 hours)
- If a dose is missed: administer as soon as remembered the same day; if the next day has arrived, skip and continue — do not double-dose
6. Premedication (as discussed)
- Paracetamol 500-1000 mg orally 30-60 min before injection for the first 5-7 days
- Taper premedication once patient is tolerating injections without systemic symptoms
- Antihistamine (cetirizine 10 mg) PRN if urticaria or pruritus develops
7. Monitoring Schedule
Laboratory Monitoring
| Timepoint | Tests |
|---|---|
| Baseline (before starting) | FBC with differential, LFTs, RFTs, CRP, Treg count (CD4+CD25+FoxP3+), LDH |
| Week 1 | FBC (check eosinophilia; Treg expansion confirmation) |
| Week 2, 4, 8, 12 | FBC with differential, LFTs, RFTs |
| Week 8, 12, 24 | Full immune panel including Treg:Tcon ratio, disease activity score |
| As clinically indicated | Treg count — expected to rise ≥3-5× by week 4; if not, reassess |
Clinical Assessment
| Timepoint | Assessment |
|---|---|
| Day 7 | First clinic visit — assess injection site reactions, flu-like symptoms, early tolerability |
| Week 4 | Clinical response assessment (disease activity score for cGvHD) |
| Week 8 | Formal response evaluation |
| Week 12 | End of initial treatment course — decision to continue, pause, or stop |
| Weekly | Patient self-report via diary or phone check-in (first 4 weeks) |
8. Response Assessment
| Response | Definition |
|---|---|
| Complete Response (CR) | Resolution of all reversible cGvHD manifestations |
| Partial Response (PR) | ≥50% improvement in at least one affected organ without worsening in others |
| Stable Disease (SD) | <50% improvement, no progression |
| Progressive Disease (PD) | Worsening in any organ or new organ involvement |
9. Dose Modifications and Withholding Criteria
| Situation | Action |
|---|---|
| Grade 1-2 injection site reaction | Continue; rotate sites; topical hydrocortisone PRN |
| Grade 3-4 injection site reaction | Withhold; reassess; consider dose reduction or discontinuation |
| Fever >38.5°C (not from infection) | Withhold until afebrile ×24h; restart with prophylactic paracetamol |
| Active infection (any grade) | Withhold until infection resolved |
| ALT/AST >5× ULN | Withhold; recheck in 1 week; resume if normalized |
| cGvHD flare / worsening | Withhold; reassess — may need additional immunosuppression |
| Significant eosinophilia (>1.5 × 10⁹/L with symptoms) | Withhold; reassess |
| Progressive disease at week 8 | Discontinue |
10. Discontinuation Criteria
- Progressive cGvHD despite 8 weeks of therapy
- Grade 3-4 non-hematologic toxicity not manageable with supportive care
- Patient request
- Development of active serious infection
- New organ failure (hepatic, renal, pulmonary)
11. Patient Education Points
| Topic | Key Message |
|---|---|
| Storage | Keep in refrigerator at all times; never freeze; bring to room temperature before use |
| Missed dose | Same day only; never double-dose |
| Injection diary | Record site, time, and any local/systemic reactions daily |
| When to call | Fever >38.5°C, severe rash/hives, shortness of breath, significant swelling at site |
| When to go to ER | Signs of systemic allergic reaction (throat swelling, difficulty breathing, drop in BP) |
| Avoid | Live vaccines during treatment; report all new medications to treating team |
| Activity | No restrictions; normal daily activities are encouraged |
12. Documentation Requirements
- Date and time of injection
- Lot number and expiry date of Proleukin vial used
- Injection site used
- Any adverse reactions observed
- Premedication given (if any)
- Patient/nurse signature